Findings from the phase 3 EMBRACA trial demonstrated that treatment with talazoparib 1 mg QD significantly improved progression-free survival (hazard ratio [HR] 0.54 [95% confidence interval (CI)] 0.41 to 0.71; P < 0.001) and patient-reported outcomes compared with chemotherapy in patients with HER2-negative advanced breast cancer and a germline BRCA1/2 mutation [19, 20]. This evidence concerns the gene BRCA1 and breast carcinoma.